Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The Vaccine Group unveils cattle vaccine trial success

4:57
 
Share
 

Manage episode 517842569 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Jeremy Salt, CEO of The Vaccine Group (TVG), a Frontier IP Group PLC (AIM:FIPP) portfolio company, talked with Proactive's Stephen Gunnion about the company's recent vaccine trial results targeting Bovine Respiratory Syncytial Virus (BRSV). Salt highlighted that BRSV is a major cause of bovine respiratory disease, responsible for annual losses of approximately £54 million in the UK alone, and nearly £6 billion globally. "This is a critical disease," Salt said, referencing data from the Pirbright Institute. The trials, conducted with the Animal and Plant Health Agency in the UK, involved vaccinating calves and subsequently exposing them to high levels of the virus under controlled conditions. The study assessed clinical outcomes, virus shedding, and lung pathology, using a well-recognised industry model. Salt emphasized that the company’s new vaccine offers advantages over existing options. Traditional vaccines, especially live or inactivated ones, have struggled due to maternal immunity interference and administration challenges. However, The Vaccine Group’s injectable candidate bypasses these issues by using a viral vector that avoids neutralisation by maternal antibodies, without the practical drawbacks of intranasal delivery. The company is now exploring licensing deals and commercial development opportunities, with Salt noting that additional funding could enable internal development through contract manufacturers. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications to stay updated. #BRSV #CattleHealth #TheVaccineGroup #AnimalVaccines #LivestockFarming #VetScience #BiotechNews #RespiratoryDisease #Agribusiness #ProactiveInvestors
  continue reading

606 episodes

Artwork
iconShare
 
Manage episode 517842569 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Jeremy Salt, CEO of The Vaccine Group (TVG), a Frontier IP Group PLC (AIM:FIPP) portfolio company, talked with Proactive's Stephen Gunnion about the company's recent vaccine trial results targeting Bovine Respiratory Syncytial Virus (BRSV). Salt highlighted that BRSV is a major cause of bovine respiratory disease, responsible for annual losses of approximately £54 million in the UK alone, and nearly £6 billion globally. "This is a critical disease," Salt said, referencing data from the Pirbright Institute. The trials, conducted with the Animal and Plant Health Agency in the UK, involved vaccinating calves and subsequently exposing them to high levels of the virus under controlled conditions. The study assessed clinical outcomes, virus shedding, and lung pathology, using a well-recognised industry model. Salt emphasized that the company’s new vaccine offers advantages over existing options. Traditional vaccines, especially live or inactivated ones, have struggled due to maternal immunity interference and administration challenges. However, The Vaccine Group’s injectable candidate bypasses these issues by using a viral vector that avoids neutralisation by maternal antibodies, without the practical drawbacks of intranasal delivery. The company is now exploring licensing deals and commercial development opportunities, with Salt noting that additional funding could enable internal development through contract manufacturers. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications to stay updated. #BRSV #CattleHealth #TheVaccineGroup #AnimalVaccines #LivestockFarming #VetScience #BiotechNews #RespiratoryDisease #Agribusiness #ProactiveInvestors
  continue reading

606 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play